ArticleNature medicine2018
p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Abstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 603 papers.
0numbers the graph read from it
0cells of the map it votes in
603citing papers in PubMed
48.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
603 citing papers in PubMed, 993 citations in OpenAlex.
- Production and Storage of High-Capacity Adenoviral Vectors for the Delivery of Advanced CRISPR Systems.Methods in molecular biology (Clifton, N.J.) · 2027Article
- CRISPR-Cas9 in Cancer Therapy: Overcoming Delivery Barriers and Off-Target Effects for Clinical Translation.Health science reports · 2026Article
- CRISPR-Enabled functional genomics in hPSCs-derived neural models for autism spectrum disorder.Metabolic brain disease · 2026Review
- Engineered Transformer Base Editor with Enhanced Editing Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable enzymes for targeted gene insertion.Nature reviews. Genetics · 2026Review
- Donor-complementary prime editing enables precise kilobase and library-compatible DNA insertions.Nature biotechnology · 2026Article
- Treatment of Huntington's disease with a pan-HTT-targeting CRISPR nuclease.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.Materials today. Bio · 2026Review
- Flying under the radar: immune-evasive DNA for genome engineering.Cell research · 2026Article
- Chemical and Structural Engineering of Guide RNAs for Precision Genome Editing: From Design Principles to Clinical Applications.Chemical biology & drug design · 2026Review
- Dissecting conserved molecular mechanisms of biological toxin activity through CRISPR screening.Biochemical Society transactions · 2026Review
- CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics.International journal of molecular sciences · 2026Review
- iSCORE-PD: an isogenic stem cell collection to research Parkinson's disease.Nature communications · 2026Article
- Engineered transformer base editor with unconstrained PAM requirements.Molecular therapy. Nucleic acids · 2026Article
- The evolution of AI-integrated genome editing and its challenges.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Inheritance entropy: A model-independent method to probe the hereditary structure of cell lineage trees.PRX life · 2026Article
- Article
- High genotoxicity of CRISPR/Cas9 versus limited efficacy of CRISPRi in chicken primordial germ cells.Poultry science · 2026Article
- Combinatorial and Inducible CRISPRa/i Enables Canalized hiPSC Forward Programming and Iterative RefinementbioRxiv : the preprint server for biology · 2026Article
543 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
20 authors at 4 institutions in 3 countries.
Robert J IhryDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Kathleen A WorringerDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Max R SalickDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Elizabeth FriasDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Daniel HoDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Kraig TheriaultDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Sravya KommineniDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Julie ChenDepartment of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Marie SondeyAbbvie, Cambridge, MA, USA.
Chaoyang YeBlueprint Medicine, Cambridge, MA, USA.
Ranjit RandhawaDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Tripti KulkarniDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Zinger YangDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8543-4841
Gregory McAllisterDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Carsten RussDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
John Reece-HoyesDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
William ForresterDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Gregory R HoffmanDepartment of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Ricardo DolmetschDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
Ajamete KaykasDepartment of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ajamete.kaykas@novartis.com.
Novartis (United States) · USAbbVie (United States) · USBlueprint Medicines (United States) · USNovartis (Switzerland) · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR/Cas9 has revolutionized our ability to engineer genomes and conduct genome-wide screens in human cells
Indexed as
Genetic EngineeringCRISPR-Associated Protein 9CRISPR-Cas SystemsCyclin-Dependent Kinase Inhibitor p21DNA Breaks, Double-Strandedfas ReceptorGene DeletionHumansPluripotent Stem CellsRNA, Guide, CRISPR-Cas SystemsRNA, MessengerTranscription, GeneticTumor Suppressor Protein p53CRISPR-Associated Protein 9Cyclin-Dependent Kinase Inhibitor p21FAS protein, humanfas ReceptorRNA, Guide, CRISPR-Cas SystemsRNA, MessengerTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.